Alzai Health (FRA:H2F) Cash Flow from Financing: €1.44 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H2F Alzai Health Corp FRA:H2F
9 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is Alzai Health Cash Flow from Financing?

Alzai Health FRA:H2F -1.62% 9 Cash Flow from Financing is €1.44 Mil as of Jan. 2026. GuruFocus rates FRA:H2F with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jan. 2026, Alzai Health paid €0.00 Mil more to buy back shares than it received from issuing new shares. It received €0.00 Mil from issuing more debt. It paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0.00 Mil from paying cash dividends to shareholders. It received €0.00 Mil on other financial activities. In all, Alzai Health spent €0.00 Mil on financial activities for the three months ended in Jan. 2026.


Alzai Health  (FRA:H2F) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Alzai Health's issuance of stock for the three months ended in Jan. 2026 was €0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Alzai Health's repurchase of stock for the three months ended in Jan. 2026 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Alzai Health's net issuance of debt for the three months ended in Jan. 2026 was €0.00 Mil. Alzai Health received €0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Alzai Health's net issuance of preferred for the three months ended in Jan. 2026 was €0.00 Mil. Alzai Health paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Alzai Health's cash flow for dividends for the three months ended in Jan. 2026 was €0.00 Mil. Alzai Health received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Alzai Health's other financing for the three months ended in Jan. 2026 was €0.00 Mil. Alzai Health received €0.00 Mil on other financial activities.


Alzai Health Cash Flow from Financing Related Terms


Alzai Health Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Alzai Health's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health Cash Flow from Financing Chart

Alzai Health Annual Data
Trend Apr25
Cash Flow from Financing
0.00

Alzai Health Quarterly Data
Jan25 Apr25 Jul25 Oct25 Jan26
Cash Flow from Financing 0.61 -0.00 1.10 -0.03 0.37
FRA:H2F
9GF Score
Alzai Health Corp FRA:H2F
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Alzai Health's Cash from Financing for the fiscal year that ended in Apr. 2025 is calculated as:

Alzai Health's Cash from Financing for the quarter that ended in Jan. 2026 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of €1.44 Mil mean?
Alzai Health (FRA:H2F) has a Cash Flow from Financing of €1.44 Mil as of Jan. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Alzai Health and its competitors.
Is Alzai Health's Cash Flow from Financing too high?
Alzai Health's current Cash Flow from Financing is €1.44 Mil. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's Cash Flow from Financing compare to VRTX and REGN?
Alzai Health's Cash Flow from Financing of €1.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Alzai Health and its competitors. Alzai Health's current Cash Flow from Financing is €1.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (FRA:H2F) has a current Cash Flow from Financing of €1.44 Mil. The current Cash Flow from Financing is €1.44 Mil. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Alzai Health (FRA:H2F), the current Cash Flow from Financing is €1.44 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Other Exchanges ALZI:Canada
Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for FRA:H2F

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price